Bianca D. Santomasso, MD, PhD

Bianca D. Santomasso, MD, PhD, assistant attending neurologist at Memorial Sloan Kettering Cancer Center, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) with chimeric antigen receptor (CAR) T-cell therapy.

The potential for relapse and the toxicities themselves both pose unique challenges with CAR T-cell therapy, Santomasso says. Some CAR T cells are administered in patients because of the risk of toxicity, so minimizing the risk of relapse and toxicities would be a great next step in the treatment paradigm. Additionally, Santomasso says it would be great if these treatments could even be moved to the outpatient setting. This has already been tested with 1 CAR T-cell therapy in clinical trials.

Videos

Bianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.

Bianca D. Santomasso, MD, PhD | Authors

Articles

Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCL